Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).
1 finding from 1 review
QoL · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
3 studies · 1417 participants
GRADE not reported
RR 6.56 [5.35, 8.03]
2 studies · 1311 participants
GRADE not reported
RR 1.36 [0.80, 2.31]
2 studies · 1311 participants
GRADE not reported
Show 7 more findings
Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
2 findings from 1 review
Participant satisfaction · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review
Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review
Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
1 study · 424 participants
GRADE not reported
Streptococcus mutans colonization reduction (narrative; no CFU data reported) · Animal caries models (mice, rats, hamsters) challenged/colonized with Streptococcus mutans; one transgenic-plant antigen-expression system
Anticaries vaccines produced a sustained reduction in Streptococcus mutans colonization on teeth in animal models (ungraded narrative synthesis; no pooled estimate).
1 finding from 1 review
no estimate extracted
Studies not reported
GRADE not reported
Development of >=1 new carious lesion (caries incidence) · Animal caries models (mice, rats, hamsters) challenged/colonized with Streptococcus mutans; one transgenic-plant antigen-expression system
In preclinical animal models, anticaries vaccines significantly reduced dental caries risk (pooled RR 0.53, 95% CI 0.46 to 0.62; random-effects), but the evidence is ungraded and limited to short-term animal studies.
1 finding from 1 review
RR 0.53 [0.46, 0.62]
Studies not reported
GRADE not reported
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole may leads to higher clearance or reduction of antibody titres (N) (a) at 12 months (b)… compared with placebo (low certainty).
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether nifurtimox changes clearance or reduction of antibody titres (N) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I
It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).
1 finding from 1 review
Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Antibody response (immunogenicity) · 9‐ to 15‐year‐old females
Two doses of HPV vaccine probably leads to lower antibody response (immunogenicity) compared with three doses of HPV vaccine (moderate certainty).
1 finding from 1 review
Antibody titres to periodontal pathogens · Adults with periodontitis
In one case-control study, depression as a marker of social isolation was associated with elevated antibody titres to periodontal pathogens at baseline and 1-year follow-up; not pooled (ungraded).
1 finding from 1 review